Phase XV, group 1 - 01.09.2023 - 30.08.2026
Ca.-No 212
Translating inter-tumor and spatial variability in ovarian cancer into individualized therapies
Israeli Partner: Nataly Kravchenko-Balasha, Hebrew University
German Partner: Benedikt Brors, DKFZ
Publications
No publications available.
Ca.-No 213
Revealing the role of MITF in UV-induced DNA repair and induction of genetic alterations in primary melanoma
Israeli Partner: Carmit Levy, Tel Aviv University
German Partner: Jeroen Krijgsveld, DKFZ
Publications
No publications available.
Ca.-No 214
Characterizing and targeting the major histocompatibility complex class II-dependent immunome in brain tumors – COMBAT
Israeli Partner: Asaf Madi, Tel Aviv University
German Partner: Lukas Bunse, Michael Kilian, DKFZ
Publications
2025 - Nature methods
2024 - npj Systems biology and applications
Ca.-No 215
Drug targeting to nuclear condensates in cells with unlimited proliferation capacity
Israeli Partner: Eran Meshorer, Hebrew University
German Partner: Karsten Rippe, DKFZ
Publications
2025 - Nature Communications
2024 - Trends in cell biology
Ca.-No 216
Development of Advanced Feasibility, Superiorization and Optimization Methods for Complex Inverse Treatment Problems in Radiation Therapy Treatment Planning
Israeli Partner: Yair Censor, University of Haifa
German Partner: Niklas Wahl, DKFZ
Publications
No publications available.
Ca.-No 217
A double-edged immunotherapeutic treatment targeting pancreatic cancer
Israeli Partner: Cyrille Cohen, Bar Illan University
German Partner: Dieter Saur, DKFZ
Publications
2025 - Frontiers in immunology